Drug intelligence / Profile preview

BM-hMSC exosomes

Development stage: Preclinical
Lead developer: Miyazaki University
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

BM-hMSC exosomes are extracellular vesicles derived from human bone marrow-derived mesenchymal stem cells (BM-hMSCs). They are being investigated as a cell-free delivery vehicle for therapeutic agents, such as microRNAs (e.g., miR-128), due to their ability to cross the blood-brain barrier and selectively home to glioma tissues. In preclinical models of glioblastoma, these exosomes have demonstrated the capacity to deliver synthetic microRNA mimics that downregulate oncogenic targets like BMI-1, thereby inhibiting tumor growth and improving survival.

Other names: bone marrow-derived human mesenchymal stem cell exosomesMSC exosomeshuman bone marrow-derived MSC exosomes

Targets

BMI1 (Polycomb complex protein BMI-1)

Beyond the preview

Go deeper on BM-hMSC exosomes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM-hMSC exosomes.

Explore the full profile